Step­ping out as a glob­al play­er, a re­struc­tured Take­da en­rolls 20,000-plus in new dengue PhI­II in a show­down with Sanofi

Christophe We­ber, pres­i­dent and chief ex­ec­u­tive of­fi­cer of Take­da Phar­ma­ceu­ti­cal Co., speaks dur­ing the 18th Nikkei Glob­al Man­age­ment Fo­rum in Tokyo, Japan  (CRED­IT: To­mo­hi­ro Ohsu­mi/Bloomberg via Get­ty Im­ages)

Last sum­mer, when Take­da set out to re­struc­ture its glob­al R&D op­er­a­tions, CEO Christophe We­ber ze­roed in on four key ar­eas: can­cer, GI, CNS dis­eases and vac­cines. Part of that com­mit­ment to vac­cines in­clud­ed a makeover in­to a glob­al play­er. And to­day the bio­phar­ma com­pa­ny took a big step for­ward in that di­rec­tion with the com­ple­tion of en­roll­ment of more than 20,000 kids in­to a piv­otal Phase III test of a new dengue vac­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.